Fingolimod for treatment and or prevention of chemotherapy-induced peripheral neuropathy in humans?
Loprinzi, C.; Harlos, B.; Staff, N.; Zahrieh, D.
Show abstract
PurposeSubstantial preclinical data support that fingolimod, a drug that dysregulates sphingolipid metabolism, could both prevent chemotherapy-induced neuropathy (CIPN) and treat established chemotherapy-induced neuropathy. MethodsTwo pilot-phase clinical trials were developed to evaluate whether fingolimod could 1) inhibit the development of paclitaxel-induced peripheral neuropathy and 2) diminish established CIPN in humans. ResultsUnfortunately, both clinical trials were not able to fulfill planned accrual goals. One of the major accrual problems was the requirement for patients to be in the clinic for 8 hours following their first oral dose of fingolimod. The prevention of paclitaxel CIPN trial accrued 2 patients, one of whom did very well without any significant CIPN while the other patient developed CIPN that led to early paclitaxel dose cessation. The treatment of established CIPN trial accrued 7 of 10 planned patients. The results from the 6 patients who started daily treatment with fingolimod did not suggest that it substantially decreased CIPN over what might have been expected from a placebo effect. ConclusionFingolimod is a clinically difficult treatment for patients to start and the limited clinical data from these protocols did not support that it was able to prevent CIPN or treat established CIPN.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A distinct four-value blood signature of pyrexia under combination therapy of malignant melanoma with BRAF/MEK-inhibitors evidenced by an algorithm-defined pyrexia score 91%
- A low molecular weight dextran sulphate, ILB(R), for the treatment of amyotrophic lateral sclerosis (ALS): an open-label, single-arm, single-centre, phase II trial 91%
- Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor 91%
Similar papers in this journal
- Assessment of levamisole HCl and thymosin α1 in two mouse models of amyotrophic lateral sclerosis 89%
- Adverse events following COVID-19 vaccination in young Japanese people: A case-control study of the risk of systemic adverse events by a questionnaire surveyShort title: COVID-19 vaccine adverse events in young Japanese 89%
- RNA expression classifiers from a model of breast epithelial cell organization to predict pathological complete response in triple negative breast cancer 87%
Similar papers in this journal
- Augmentation of extracellular ATP synergizes with chemotherapy in triple negative breast cancer 91%
- Meta-Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma 90%
- mRNA-COVID19 vaccination can be considered safe and tolerable for frail patients 90%
Similar papers in this journal
- The efficacy of CB-103, a first-in-class transcriptional Notch inhibitor, in preclinical models of breast cancer 91%
- Development of a Metastatic Uveal Melanoma Prognostic risk Score (MUMPS) for use in patients receiving immune checkpoint inhibitors 91%
- Differences in durability of PARP inhibition by clinically approved PARP inhibitors: implications for combinations and scheduling 90%
Similar papers in this journal
- RepCOOL: Computational Drug Repositioning Via Integrating Heterogeneous Biological Networks 87%
- Impact of immediate cryopreservation on the establishment of patient derived xenografts from head and neck cancer patients. 87%
- Immune Cell Profiles and Cytokine Levels of Patients with Interstitial Cystitis/Bladder Pain Syndrome 85%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.